Sirolimus and its analogs and its effects on vascular diseases

Current Pharmaceutical Design

Volumn 16, Issue 36, 2010, Pages 4002-4011

  Adelman, Steven J ^a  

^a Vascular Strategies LLC   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Immune response; Sirolimus; Stents; Target of rapamycin (TOR)

Indexed keywords

ALBUMIN; APOLIPOPROTEIN E; BIOLIMUS; CHOLESTEROL; CYCLOSPORIN A; CYPHER; DEXTRAN; EVEROLIMUS; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PERFLUBUTANE; RAPAMYCIN; RAPAMYCIN DERIVATIVE; TACROLIMUS; TARGET OF RAPAMYCIN KINASE; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ANTIINFLAMMATORY ACTIVITY; ARTERY INJURY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CHOLESTEROL BLOOD LEVEL; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; ENZYME INHIBITION; HUMAN; IMMUNE RESPONSE; IN-STENT RESTENOSIS; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR DISEASE;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; SIROLIMUS; VASCULAR DISEASES;

EID: 79952681720     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210794454923     Document Type: Article

References (81)

1. American Heart Association Statistics 2010: http://www.americanheart.org/downloadable/heart/1265665152970DS-3241HeartStrokeUpdate_2010.pdf
2. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26
3. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
4. Sheikine Y, Hansson GK. Chemokines and atherosclerosis. Ann Med 2004; 36: 98-118
5. Lucas AD, Greaves DR. Atherosclerosis: role of chemokines and macrophages. Expert Rev Mol Med 2001; 2001: 1-16.
6. Stemme S, Hansson GK. Immune mechanisms in atherogenesis. Ann Med 1994; 26: 141-6.
7. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003; 35: 7S-14S.
8. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three dimensional intravascular ultrasound study. Circulation 2001; 103: 192-5.
9. Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from patho-physiology to practice. J Am Coll Cardiol 2009; 54: 2129-38.
10. Hansson GK. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost 2009; 7 (Suppl 1): 328-331.
11. White RA, Cavaye DM. Pathology of arterial disease: influence of morphology and distribution of lesions on interventional therapy. J Cardiovasc Surg (Torino) 1993; 34: 105-13.
12. Schoenhagen P, Nissen SE. Assessing coronary plaque burden and plaque vulnerability: atherosclerosis imaging with IVUS and emerging noninvasive modalities. Am Heart Hosp J 2003; 1: 164-9.
13. Schoenhagen P, McErlean ES, Nissen SE. The vulnerable coronary plaque. J Cardiovasc Nurs 2000; 15: 1-12.
14. Stone GW. PROSPECT Study provides new insight into role of vulnerable plaque in heart disease. This article was posted on the diagnostic and invasive cardiology website on [October 8, 2009].
15. BARI 2D Study Group. A randomized trial of therapies for Type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360: 2503-15.
16. Meier B. Plaque stabilization in coronary artery disease: introduction. Heart 2004; 90: 1384.
17. Tanaka A, Shimada K, Sano T. Multiple plaque rupture and C reactive protein in acute myocardial infarction. J Am Coll Cardiol 2005; 45: 1594-9.
18. Nissen SE. Pathobiology, not angiography, should guide management in acute coronary syndrome/non-ST-segment elevation myocardial infarction: the non-interventionist's perspective. J Am Coll Cardiol 2003; 2005; 41: 103S.
19. Serruys PW, Luijten HE, Beatt KJ, et al. Incidence of restenosis after successful angioplasty: a time related phenomenon quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 1988; 77: 361-71.
20. Glagov S. Intimal hyperplasia, vascular modeling, and the resteno-sis problem. Circulation 1994; 89: 2888-91.
21. Edelman ER, Rogers C. Hoop dreams. Stents without restenosis. Circulation 1996; 94: 1199-202.
22. Toutouzasa K, Colombob A, Stefanadisa C. Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J 2004; 25: 1679-87.
23. Breuss JM, Cejna M, Bergmeister H, et al. Activation of nuclear factor-kappa B significantly contributes to lumen loss in a rabbit iliac artery balloon angioplasty model. Circulation 2002; 105: 633-8.
24. Meiners S, Laule M, Rother W, et al. Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation 2002; 105: 483-9.
25. Grewe PH, Deneke T, Machraoui A, Barmeyer J, Müller KM. Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. J Am Coll Cardiol 2000; 35: 157-63.
26. Hokimoto S, Oike Y, Saito T, et al. Increased expression of mono-cyte chemoattractant protein-1 in atherectomy specimens from patients with restenosis after percutaneous transluminal coronary an-gioplasty. Circ J 2002; 66: 114-6.
27. Abbate A, Biondi-Zoccai GG, Brugaletta S, Liuzzo G, Biasucci LM. C-reactive protein and other inflammatory biomarkers as predictors of outcome following acute coronary syndromes. Semin Vasc Med 2003; 3: 375-83
28. Shah SH, Newby LK. C-reactive protein: a novel marker of cardiovascular risk. Cardiol Rev 2003; 11: 169-79.
29. Walter DH, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Schäch-inger V, Zeiher AM. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001; 37: 839-46.
30. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999; 34: 1512-21.
31. Patti G, Di Sciascio G, D'Ambrosio A, Dicuonzo G, Abbate A, Dobrina A. Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. Am J Cardiol 2002; 89: 372-6.
32. Pietersma A, Kofflard M, de Wit LE, et al. Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation 1995; 91: 1320-5
33. Moreno PR, Bernardi VH, Lopez-Cuellar J, et al. Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina. Circulation 1996; 94: 3098-102.
34. Stefanadis C, Toutouzas K, Tsiamis E, et al. Increased local temperature in human coronary atherosclerotic plaques: an independent predictor of clinical outcome in patients undergoing a percutaneous coronary intervention. J Am Coll Cardiol 2001; 37: 1277-83.
35. Sehgal SN, Molnar-Kimber K, Ocain TD, Weichman BM. Rapamycin: a novel immunosuppressive macrolide. Med Res Rev 1994; 14: 1-22.
36. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in VSMC. Circ Res 1995; 76: 412-7.
37. Wiederrecht GJ, Sabers CJ, Brunn GJ, Martin MM, Dumont FJ, Abraham RT. Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. Prog Cell Cycle Res 1995; 1: 53-71.
38. Suthanthiran M, Morris RE, Strom TB. Immunosuppressants: cellular and molecular mechanisms of action. Am J Kidney Dis 1996; 28: 159-72.
39. Halloran PF. Molecular mechanisms of new immunosuppressants. Clin Transplant 1996; 10: 118-23.
40. Cardenas ME, Zhu D, Heitman J. Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. Curr Opin Nephrol Hypertens 1995; 4: 472-7.
41. Dumont FJ, Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci 1996; 58: 373-95.
42. Sun J, Marx SO, Chen HJ, Poon M, Marks AR, and Rabbani LE. Role for p27(Kip1) in vascular smooth muscle cell migration. Circulation 2001; 103: 2967-72.
43. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits VSMC migration. J Clin Invest 1996; 98: 2277-83.
44. Reusch HP, Zimmermann S, Schaefer M, Paul M, Moelling K. Regulation of Raf by Akt controls growth and differentiation in vascular smooth muscle cells. J Biol Chem 2001; 276: 33630-7.
45. Martin KA, Rzucidlo EM, Merenick BL, et al. The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation. Am J Physiol Cell Physiol 2004; 286: C507-7.
46. Gregory C, Huie P, Billingham M, Morris R. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Transplantation 1993; 55: 1409-18.
47. Gallo R, Padurean A, Toschi V, et al. Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries. Circulation 1998; 97: 581-8.
48. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries bytargeting regulators of the cell cycle. Circulation 1999; 99: 2164-70.
49. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-80.
50. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-23.
51. Klugherz BD, Llanos G, Lieuallen W, et al. Twenty-eight-day efficacy and pharmacokinetics of the sirolimus-eluting stent. Coron Artery Dis 2002 13: 183-8.
52. Kipshidze NN, Tsapenko MV, Leon MB, Stone GW, Moses JW. Update on drug-eluting coronary stents. Expert Rev Cardiovasc Ther 2005; 3: 953-68.
53. Mehilli J, Kastrati A, Byrne RA, et al. Paclitaxel- versus sirolimus eluting stents for unprotected left main coronary artery disease. LEFT-MAIN intracoronary stenting and angiographic results: drug-eluting stents for unprotected coronary left main lesions study investigators. J Am Coll Cardiol 2009; 53: 1760-8.
54. Millauer N, Jüni P, Hofmann A, et al. Sirolimus versus paclitaxel coronary stents in clinical practice. Catheter Cardiovasc Interv 2010; n/a. doi:10.1002/ccd.22597
55. Hausmann D, Johnson JA, Sudhir K, et al. Angiographically silent atherosclerosis detected by intravascular ultrasound in patients with familial hypercholesterolemia and familial combined hyperlipide-mia: correlation with high density lipoproteins. J Am Coll Cardiol 1996; 27: 1562-70.
56. Rioufol G, Finet G, Ginon I, et al. A. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation 2002; 106: 804-8.
57. Ridker PM, Morrow DA. C-reactive protein, inflammation, and coronary risk. Cardiol Clin 2003; 21: 315-25.
58. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004: 109(21 Suppl 1): II2-10.
59. Libby P, Ridker PM. Inflammation and atherosclerosis: role of Creactive protein in risk assessment. Am J Med 2004 Mar 22; 116 Suppl 6A: 9S.
60. Elloso MM, Azrolan N, Sehgal SN, et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant 2003; 3: 562-9.
61. Basso MD, Nambi P, Adelman SJ. Effect of sirolimus on the cholesterol content of aortic arch in ApoE knockout mice. Transplant Proc 2003; 35: 3136-8.
62. Waksman R, Burnett MS, Gulick CP, et al. Oral rapamycin inhibits growth of atherosclerotic plaque in apoE knock-out mice. Cardio-vasc Radiat Med 2003; 4: 34-8.
63. Naoum JJ, Woodside KJ, Zhang S, Rychahou PG, Hunter GC. Effects of rapamycin on the arterial inflammatory response in atherosclerotic plaques in Apo-E knockout mice. Transplant Proc 2005; 37: 1880-4
64. Nührenberg TG, Voisard R, Fahlisch F, et al. Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty. FASEB J 2005; 19: 246-8.
65. Ikonen TS, Gummert JF, Hayase M, et al. Sirolimus (Rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation 2000; 70: 969-75.
66. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108: 48-53.
67. Eisen H, Kobashigawa J, Starling RC, Valantine H, Mancini D. Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors. Transplant Proc 2005; 37(4 Suppl): 4S.
68. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004; 110: 2694-700.
69. Bekeredjian R, Grayburn PA, Shohet RV. Use of ultrasound contrast agents for gene or drug delivery in cardiovascular medicine. J Am Coll Cardiol 2005; 45: 329-35.
70. Tsutsui JM, Xie F, Porter RT. The use of microbubbles to target drug delivery. Cardiovasc Ultrasound 2004; 2: 23.
71. Villanueva FS, Jankowski RJ, Manaugh C, Wagner WR. Albumin microbubble adherence to human coronary endothelium: implications for assessment of endothelial function using myocardial contrast echocardiography. J Am Coll Cardiol 1997; 30: 689-93.
72. Villanueva FS, Wagner WR, Vannan MA, Narula J. Targeted ultrasound imaging using microbubbles. Cardiol Clin 2004; 22: 283-98.
73. Lindner JR, Ismail S, Spotnitz WD, Skyba DM, Jayaweera AR, Kaul S. Albumin microbubble persistence during myocardial contrast echocardiography is associated with microvascular endothelial glycocalyx damage. Circulation 1998; 98: 2187-94.
74. Lindner JR, Dayton PA, Coggins MP, et al. Noninvasive imaging of inflammation by ultrasound detection of phagocytosed micro-bubbles. Circulation 2000; 102: 531-8.
75. Lindner JR, Coggins MP, Kaul S, et al. Microbubble persistence in the microcirculation during ischemia/reperfusion and inflammation is caused by integrin- and complement-mediated adherence to activated leukocytes. Circulation 2000; 101: 668-75.
76. Tsutsui JM, Xie F, Cano M, et al. Detection of retained microbub-bles in carotid arteries with real-time low mechanical index imaging in the setting of endothelial dysfunction. J Am Coll Cardiol 2004; 44: 1036-46.
77. Anderson DR, Tsutsui JM, Xie F, Radio SJ, Porter TR. The role of complement in the adherence of microbubbles to dysfunctional arterial endothelium and atherosclerotic plaque. Cardiovasc Res 2007; 73: 597-606.
78. Kipshidze NN, Porter TR, Dangas G, et al. Novel site-specific systemic delivery of Rapamycin with perfluorobutane gas micro-bubble carrier reduced neointimal formation in a porcine coronary restenosis model. Catheter Cardiovasc Interv 2005; 64: 389-94.
79. Feinstein SB. The powerful microbubble: from bench to bedside, from intravascular indicator to therapeutic delivery system, and beyond. Am J Physiol Heart Circ Physiol 2004; 287: H450-7.
80. Kipshidze NN, Porter, TR, Dangas G, et al. Systemic targeted delivery of antisense with perflourobutane gas microbubble carrier reduced neointimal formation in the porcine coronary restenosis model. Cardiovasc Radiat Med 2003; 4: 152-9.
81. Kolodgie FD, John M, Khurana C, et al. Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation 2002; 106: 1195-8.